Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
Iovance Biotherapeutics (IOVA) saw its shares jump 256% in Q3, making it the top-performing mid-cap stock in the US market, driven by strong demand for its cancer treatments Amtagvi and Proleukin. The company raised its full-year 2026 revenue guidance to $410-$420 million, a significant increase from 2025, with analysts subsequently raising price targets. Institutional investor confidence also increased, with hedge funds boosting their positions in the stock.
What’s Behind Iovance Biotherapeutics (IOVA) Latest Move?
Iovance Biotherapeutics (IOVA) recently raised its 2026 revenue outlook to US$410-420 million due to strong demand for Amtagvi and Proleukin, leading to a significant share price surge. While the stock has seen a 78.99% gain in 30 days and 243.85% in 90 days, its 5-year return is still down 44.45%, indicating a recent shift from poor performance to strong optimism. Despite ongoing net losses, the company is viewed by some as undervalued, with a fair value of $18 compared to its last close of $14.82, though others consider it expensive based on sales multiples.
IOVANCE BIOTHERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $20 FROM $9
H.C. Wainwright has significantly increased its target price for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) shares, raising it to $20 from the previous $9. This revised target price indicates a strong positive outlook from the analytical firm regarding the biopharmaceutical company's future performance. The article, sourced from Reuters and published by Webull, focuses solely on this analyst rating update.
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Iovance Biotherapeutics has appointed Noah Berkowitz, M.D., Ph.D., as its new Chief Medical Officer, effective September 30, 2026. Dr. Berkowitz brings extensive experience in global drug development and regulatory approvals for cancer and blood disorders, previously holding leadership roles at Arvinas Pharmaceuticals, Bristol Myers Squibb, and Novartis. His appointment is expected to help Iovance advance its TIL therapy platform for various solid tumor cancers and expand its market reach.
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Iovance Biotherapeutics has appointed Noah Berkowitz, M.D., Ph.D., as its Chief Medical Officer, effective September 30, 2026. Dr. Berkowitz brings extensive experience in global drug development, including regulatory approvals for cell therapies and targeted protein degradation, which will be crucial as Iovance expands its TIL platform. He will focus on broadening the application of TIL technology for various solid tumor cancers and treatment settings.
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Iovance Biotherapeutics (IOVA) stock is trading flat after hitting a new 52-week high, driven by increased full-year 2026 revenue guidance to $410 million-$420 million. This guidance hike is attributed to strong U.S. patient demand for Amtagvi and Proleukin, with product revenue hitting a record $99.3 million in Q2. The company is also expanding its Authorized Treatment Center network, aiming for 110 active centers by year-end 2026 to support commercial execution.
IOVA Stock Price and Chart — NASDAQ:IOVA
This page provides a comprehensive overview of Iovance Biotherapeutics, Inc. (IOVA) stock, including its current price, historical performance, key financial metrics, upcoming earnings dates, and analyst forecasts. It also details the company's business activities in developing cell therapies for cancer treatment and features recent news and trading ideas related to the stock.
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics (IOVA) saw a significant 31.5% stock surge after raising its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. While the company expects increased revenues and a reduced quarterly loss per share, its Zacks Rank is #3 (Hold), and analysts advise monitoring earnings estimate revisions for sustained gains.
Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%
Iovance Biotherapeutics (IOVA) saw its shares jump over 31% after raising its full-year revenue growth guidance by as much as 60%. The company now expects $410 million to $420 million in revenues, driven by strong demand for its cancer treatments Amtagvi and Proleukin and a record second quarter. Analysts, including HC Wainwright and TD Cowen, have upgraded their price targets for IOVA, reflecting increased optimism about its future performance.
Iovance Raises 2026 Revenue Guidance to $410 Million-$420 Million
Iovance Biotherapeutics (NASDAQ:IOVA) has increased its full-year 2026 total revenue guidance to $410 million-$420 million, up from the previous forecast of $350 million-$370 million. This revision, representing a 15% increase at the midpoint, is driven by strong US demand for Amtagvi and Proleukin, as well as record second-quarter product revenue of $99.3 million. The company expects to continue expanding its network of authorized treatment centers, targeting at least 110 by the end of 2026.
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday
CarMax (NYSE: KMX) reported better-than-expected Q2 earnings and sales, causing its shares to jump. Several other companies, including Iovance Biotherapeutics (NASDAQ: IOVA), Carnival Corporation (NYSE: CCL), and Perella Weinberg Partners (NASDAQ: PWP), also saw significant stock gains due to strong financial results, raised guidance, or acquisition talks. Despite these positive movements, the Dow Jones index was down on Tuesday.
Iovance Biotherapeutics Stock Draws Bullish Targets As Amtagvi Launch Turns
Iovance Biotherapeutics (NASDAQ: IOVA) stock has seen an 18.17% increase following positive sentiment regarding its cancer therapy progress, particularly the Amtagvi launch. Analysts from Barclays and Goldman Sachs have raised their price targets to $15, citing strong physician feedback and the "inflection" point of Amtagvi's commercial execution. The company's upcoming lung cancer data for lifileucel and strategic collaborations are also contributing to bullish expectations among traders.
Iovance shares jump in premarket as raised outlook clears consensus views
Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw its shares jump over 14% in premarket trading after raising its full-year 2026 revenue outlook to between $410 million and $420 million, significantly above Wall Street expectations. This revised forecast, driven by strong domestic adoption of Amtagvi and sustained Proleukin sales, signals accelerating commercial momentum. The company attributes this to robust patient demand and an expanded authorized treatment center network, aiming for profitability through operational efficiencies and ongoing clinical trials for lifileucel.
Iovance Biotherapeutics Raises 2026 Revenue Guidance Outlook
Iovance Biotherapeutics (IOVA) has increased its full-year 2026 total revenue guidance to $410 million to $420 million, marking a 15% midpoint increase and implying nearly 60% annual growth. This updated outlook is driven by strong U.S. demand for Amtagvi and Proleukin, as well as record Q2 product revenue of $99.3 million. The company expects to expand its network of authorized treatment centers to at least 110 by year-end, further supporting its commercial momentum.
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, up from the previous range of $350-$370 million, driven by strong demand for Amtagvi and Proleukin. This new guidance represents a $55 million increase at the midpoint and implies nearly 60% annual revenue growth. The company also reported record second-quarter total product revenue of $99.3 million and is expanding its authorized treatment center network.
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410 to $420 million, up from the previous range of $350 to $370 million. This raised outlook, representing a 15% increase at the midpoint, is attributed to strong U.S. demand for its products Amtagvi and Proleukin. The company also reported record second-quarter 2026 revenue and continues to expand its authorized treatment center network.
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs
Goldman Sachs has set a price target of $15.00 per share for Iovance Biotherapeutics. This indicates an analyst's valuation and outlook for the company's stock performance. Investors and market watchers will likely consider this target in their assessment of Iovance Biotherapeutics.
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD
Iovance Biotherapeutics (IOVA) stock has reached a new 52-week high of $10.98, reflecting a significant upward trend with a 434.65% one-year return and a 295.6% year-to-date gain. Despite InvestingPro suggesting the stock may be overvalued, the company recently surpassed Wall Street's Q2 2026 revenue expectations with strong sales of its cancer therapy Amtagvi, leading to positive analyst ratings and raised price targets.
Why Iovance Biotherapeutics Stock Was on Fire Today
Iovance Biotherapeutics (NASDAQ: IOVA) saw its stock rise by almost 6% due to a bullish analyst report from Goldman Sachs. Analyst Andrea Newkirk resumed coverage, rating Iovance a "buy" with a $15 price target, citing strong Q2 performance of its drug Amtagvi and increasing demand as a second-line melanoma treatment. The report suggests that Amtagvi is entering a significant growth phase as operational hurdles are being overcome.
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD
Iovance Biotherapeutics (IOVA) stock has reached a new 52-week high of $10.98, reflecting a significant upward trend with a 1-year return of 434.65% and a year-to-date gain of 295.6%. This milestone follows a strong second-quarter 2026 performance, where the company surpassed Wall Street expectations with record revenue of $99.31 million, largely driven by sales of its cancer therapy Amtagvi. Analysts from Goldman Sachs, TD Cowen, and UBS have responded positively, initiating or raising price targets for the stock.
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo Finance
The article provides an options chain for Iovance Biotherapeutics, Inc. (IOVA) on Yahoo Finance. It shows real-time price data for IOVA, including its performance at market close and pre-market, but indicates that there are no calls or puts available in the options chain for the specified date.
Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history
This article provides a detailed overview of Iovance Biotherapeutics, Inc. (IOVA), including its current stock price, historical performance, and company profile. It highlights IOVA's commercial-stage biopharmaceutical operations, focusing on cell therapies for various cancers, and presents financial data, analyst insights, and earnings trends. The company's key products, clinical pipeline, and collaborative agreements are also mentioned, along with comparisons to the S&P 500.
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History
This article provides comprehensive financial information for Iovance Biotherapeutics, Inc. (IOVA), including its stock price, historical data, analyst ratings, and company overview. It highlights the company's focus on developing and commercializing cell therapies for cancer, particularly its product Amtagvi, and details its performance metrics and financial health. The report also includes recent news, earnings trends, and analyst insights.
Iovance Biotherapeutics Stock: 6 Straight Green Days, Up 26%
Iovance Biotherapeutics (IOVA) stock has seen a significant surge, gaining 26% over six consecutive trading days and adding approximately $950 million to its market value. While the company demonstrates strong revenue growth of 34.5% over the last twelve months, its operating margin remains negative at -91.1%, indicating substantial losses. This article highlights that while the streak draws market attention, investors should evaluate the company's fundamentals rather than chasing momentum.
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced it granted inducement awards to three new employees as required by NASDAQ Listing Rule 5635(c)(4). These awards included non-statutory stock options to purchase 39,000 shares of common stock and restricted stock unit awards for 19,500 shares, vesting over four years subject to continued employment. The grants were approved by the company's compensation committee and are separate from the 2023 Long-Term Incentive Plan.
Iovance Biotherapeutics stock hits 52-week high at 9.36 USD
Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $9.36, trading at $9.38 with a $4.2 billion market cap, reflecting a 215% year-to-date return. This surge follows strong Q2 2026 results, including record revenue of $99.31 million driven by Amtagvi sales, and narrower-than-expected losses, leading to raised price targets from UBS and TD Cowen. Despite appearing overvalued by InvestingPro, the company shows significant growth and investor confidence.
How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing
This article analyzes Iovance Biotherapeutics Inc. (IOVA) using AI models, indicating strong sentiment across all horizons and significant upside potential due to the absence of resistance levels. It presents three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report emphasizes the potential for alpha generation, beta reduction, and risk control through these strategies.
IOVA Maintained by TD Cowen -- Price Target Raised to $10.00
Iovance Biotherapeutics Inc (IOVA) received a maintained Buy rating from TD Cowen, with analyst Nicholas Lorusso raising the price target from $7.00 to $10.00, reflecting increased confidence in the company's future. Despite this positive outlook and a current market price of $8.24, IOVA has a low GF Score™ of 34/100, indicating significant weaknesses in profitability and valuation. The company, a clinical-stage biopharmaceutical firm focusing on personalized cancer therapies, remains unprofitable with a high Price-to-Sales ratio.
Weekly Recap: IOVA trial updates and Mizuho raises price target to $11
Iovance Biotherapeutics Inc (IOVA) is gaining attention due to upcoming trial data releases, including late-October SARATOGA soft-tissue sarcoma data and frontline melanoma results. Additionally, a Q4 pivotal NSCLC update and potential UK Amtagvi approval are anticipated. Mizuho has raised its price target for IOVA to $11, reflecting a revised analyst valuation.
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman
Iovance Biotherapeutics (NASDAQ: IOVA) is facing a securities class action lawsuit alleging that the company misled investors about its growth potential and ability to meet demand for its cancer treatments. The lawsuit claims Iovance made "overwhelmingly positive statements" while concealing "material adverse facts" regarding its readiness, leading to a significant stock price drop after a downward revision of its full-year revenue guidance. Hagens Berman is investigating these claims and encouraging affected investors to come forward.
IOVA
This Finviz page provides a comprehensive overview of Iovance Biotherapeutics Inc. (IOVA), including its current stock performance, key financial metrics, insider and institutional ownership data, and various performance indicators. The stock closed at $8.29, experiencing a significant percentage change of -7.79% on the day. The article details market capitalization, income, sales, and a range of valuation ratios.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) reported a Q2 loss of $0.11 per share, exceeding the Zacks Consensus Estimate of a $0.17 loss, marking a 35.29% earnings surprise. The company also surpassed revenue expectations with $99.31 million against an estimate, showing significant growth from the previous year. IOVA's stock has seen a 59% increase year-to-date, and it currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.
Biotech company Iovance grants 20 new employees options with an $8.99 exercise price
Iovance Biotherapeutics (NASDAQ: IOVA) announced the grant of inducement stock options covering 240,135 shares to twenty new non-executive employees on August 20, 2026. The options have an exercise price of $8.99, matching the closing price on the grant date. These awards, issued under the company's Amended and Restated 2021 Inducement Plan, will vest over three years to aid employee retention.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 240,135 shares of its common stock to twenty new non-executive employees. These awards, granted on August 20, 2026, are part of the company's Amended and Restated 2021 Inducement Plan under Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $8.99 and vest over a three-year period, contingent on continued employment.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 240,135 shares of its common stock to twenty new, non-executive employees on August 20, 2026. These grants were made under Iovance's Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with an exercise price of $8.99 per share and a three-year vesting schedule. The company specializes in TIL cell therapies for solid tumors, with its FDA-approved Amtagvi® for advanced melanoma.
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8% - Here's Why
Iovance Biotherapeutics (NASDAQ:IOVA) saw its stock price drop by 5.8% to $8.47, despite exceeding quarterly earnings and revenue expectations. The company reported a loss of $0.11 per share against an estimated $0.13 loss and revenue of $198.63 million, marking a 65.7% year-over-year increase. Despite this, Iovance remains unprofitable with a negative net margin of 89.11%, and analyst ratings are mixed, with a consensus "Hold" and an average price target of $8.75.
IOVA Stock Pulls Back As Biotech Momentum Cools
Iovance Biotherapeutics Inc. (IOVA) stock has experienced a pullback, trading down 7.01% after a significant multi-week rally that saw it nearly double from late July lows. Despite strong revenue growth and a solid cash position, the company faces heavy losses, placing it in a high-risk biotech category. Traders are closely watching for signs of consolidation or further pullback, emphasizing disciplined trading strategies due to the stock's volatility.
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations
UBS has increased its price target for Iovance Biotherapeutics (IOVA) to $7.00 from $4.00, following the company's Q2 performance that significantly surpassed analyst expectations, driven by strong sales of its cancer therapy Amtagvi. Despite the positive financial results and a substantial stock surge, UBS maintained a "Neutral" rating due to valuation concerns and potential risks like competitive pressure. The raised price target and positive earnings revisions from other analysts indicate growing confidence in the company's growth trajectory, although some caution remains regarding the stock's already impressive rally.
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics (NASDAQ: IOVA) stock reached a 52-week high despite no new company-specific news, largely attributed to breakthrough data from Moderna and Merck & Co's individualized cancer therapy for advanced skin cancer. Iovance's own Amtagvi, an FDA-approved TIL therapy for advanced melanoma, and positive early data for its TIL cell therapy in soft-tissue sarcomas also contribute to investor interest, along with strong Q2 earnings and raised price targets from analysts.
IOVA Stock Climbs As Earnings Beat Fuels Guidance Rethink
Iovance Biotherapeutics Inc. (IOVA) stock climbed by 7.2% following a strong Q2 2026 earnings report, which saw record revenue of $99.3M, a 66% year-over-year increase, primarily driven by Amtagvi demand. The company also beat Wall Street expectations for per-share loss and indicated that its 2026 revenue guidance of $350M–$370M is under review for a potential upward revision in Q3. This performance has led multiple banks to raise their price targets for IOVA, signaling growing institutional interest and positive momentum for the commercial-stage biotech.
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA)
Iovance Biotherapeutics (IOVA) reported a strong Q2 '26 with significant Amtagvi sales and anticipates further growth. The company's maturing clinical pipeline, especially the imminent NSCLC readout, positions it for substantial upside, given NSCLC's larger market potential compared to melanoma. While a competitor, IMTX, is expected to release melanoma trial results in H1 '27, IOVA faces risks such as clinical data disappointments, delays, or subpar sales.
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 11% Following Analyst Upgrade
Iovance Biotherapeutics (NASDAQ:IOVA) saw its stock price jump 11% after Mizuho raised its price target from $10 to $11, maintaining an "outperform" rating. The company reported strong Q2 results, exceeding EPS and revenue estimates. While analyst sentiment is mixed with a consensus "Hold" rating, institutional investors have increased their stakes in IOVA.
Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus
Iovance Biotherapeutics (IOVA) is back in focus after reporting strong Q2 2026 results, with revenue of $99.31 million and narrowed losses, alongside a positive full-year revenue guidance. The stock has seen significant recent gains, with a 42% return in 30 days and 184% over one year, fueled by the approval of its first product, Amtagvi. While one valuation model suggests the stock is undervalued with a fair value of $18, another indicates it trades at a premium P/S ratio compared to its own historical average, reflecting investor optimism about its growth prospects and execution ability.
IOVA Maintained by Mizuho -- Price Target Raised to $11.00
Mizuho has maintained an "Outperform" rating on Iovance Biotherapeutics (IOVA) and raised its price target from $10.00 to $11.00, signaling optimism for the company's future in biotechnology. Despite this positive analyst sentiment, IOVA's GF Score™ of 34/100 and high price-to-sales ratio suggest that investors should approach the stock with caution due to low profitability and potential overvaluation.
Rice Hall James & Associates LLC Acquires Shares of 1,539,840 Iovance Biotherapeutics, Inc. $IOVA
Rice Hall James & Associates LLC has acquired 1,539,840 shares of Iovance Biotherapeutics (NASDAQ:IOVA) for approximately $6.4 million, representing about 0.34% of the company. Institutional investors and hedge funds now own 77.03% of IOVA. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $8.00, Iovance recently reported strong quarterly revenues of $198.63 million, significantly exceeding estimates, and a narrower-than-expected loss of $0.11 per share.
Iovance Biotherapeutics Inc : Baird Assumes C
Baird has initiated coverage on Iovance Biotherapeutics Inc. (IOV) with an Outperform rating and a price target of $24.00. This new coverage suggests a positive outlook on the company's future performance.
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA
Bank of America Corp DE significantly reduced its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by selling 5.79 million shares, retaining 8.49 million shares valued at approximately $29.8 million. Despite this reduction, institutional ownership remains high at 77.03%, with other firms like Dimensional Fund Advisors and Vanguard Group Inc. increasing their positions. Analysts have a mixed sentiment with a consensus "Hold" rating and a target price of $8.00, while the company recently beat quarterly EPS estimates and reported strong revenue growth.
Iovance Biotherapeutics Q2 Earnings Call Highlights
Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue of $99.3 million, up 66% year-over-year, driven by strong demand for its Amtagvi TIL therapy. The company exceeded its quarterly revenue forecast and is reviewing its full-year 2026 guidance, expecting continued demand growth. Iovance expanded its authorized treatment center network to over 95 and made significant pipeline advancements, including FDA Fast Track designation for lifileucel in two sarcoma settings and promising early results in gynecologic cancers.
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026
Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI readings and price trading above upper Bollinger Bands suggest the rally is stretched. The article advises close attention to the 6.56 to 7.20 range to determine if the next move will be a continuation or consolidation.
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com
Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year. The company's revenue grew by 35% year-over-year to $325 million in Q2 2026. This performance, along with strong Q2 earnings that surpassed Wall Street expectations, highlights investor confidence despite InvestingPro suggesting the stock might be slightly overvalued.
